MCID: CLN015
MIFTS: 65

Colon Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Colon Adenocarcinoma

MalaCards integrated aliases for Colon Adenocarcinoma:

Name: Colon Adenocarcinoma 12 54 6 15 17
Adenocarcinoma of Colon 12 71
Adenocarcinoma of the Colon 12
Colonic Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:234
NCIt 50 C4349
SNOMED-CT 67 255082000
UMLS 71 C0338106

Summaries for Colon Adenocarcinoma

Disease Ontology : 12 A colon carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colon Adenocarcinoma, also known as adenocarcinoma of colon, is related to adenocarcinoma and colorectal adenocarcinoma. An important gene associated with Colon Adenocarcinoma is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Pathways of neurodegeneration - multiple diseases and Toll-like Receptor Signaling Pathway. The drugs Carboplatin and Oxaliplatin have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and lymph node, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development... more...

Related Diseases for Colon Adenocarcinoma

Diseases related to Colon Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 622)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 32.6 TP53 PTGS2 PIK3CA MSH6 CTNNB1 CEACAM5
2 colorectal adenocarcinoma 31.5 TYMS TP53 PTGS2 MSH6 KRT20 CTNNB1
3 clear cell adenocarcinoma 31.5 TP53 PIK3CA KRT20
4 adenoma 31.2 TP53 PTGS2 PIK3CA ODC1 MSH6 KRT20
5 familial adenomatous polyposis 31.1 TP53 PTGS2 ODC1 MSH6 CTNNB1 CDH1
6 gastrointestinal carcinoma 31.0 TYMS TP53 KRT20 CEACAM5
7 colon adenoma 31.0 CTNNB1 CASP3 APC
8 lynch syndrome 31.0 TP53 PIK3CA MSH6 CTNNB1 BRAF BAX
9 lung cancer susceptibility 3 31.0 TP53 PTGS2 PIK3CA KRT20 CTNNB1 CEACAM5
10 gastrointestinal stromal tumor 31.0 TP53 PTGS2 CDH1 CASP3 BRAF APC
11 transitional cell carcinoma 31.0 TP53 PTGS2 KRT20 CDH1 BRAF
12 papillary adenocarcinoma 30.9 TP53 CEACAM5 CDH1
13 mucinous adenocarcinoma 30.9 TP53 KRT20 CEACAM5
14 villous adenoma 30.9 TP53 KRT20 CEACAM5 BRAF APC
15 esophageal cancer 30.9 TYMS TP53 PTGS2 PIK3CA CTNNB1 CEACAM5
16 intrahepatic cholangiocarcinoma 30.9 TP53 KRT20 CTNNB1 CDH1 APC
17 carcinosarcoma 30.9 TP53 PIK3CA CTNNB1 CDH1
18 breast adenocarcinoma 30.8 TP53 PIK3CA ODC1 BAX ABCB1
19 sarcoma 30.8 TP53 PTGS2 PIK3CA CTNNB1 CASP3 BRAF
20 leukemia, chronic lymphocytic 30.8 TP53 CASP3 BRAF BAX APC ABCB1
21 cholangiocarcinoma 30.8 TP53 PTGS2 PIK3CA KRT20 CTNNB1 CEACAM5
22 appendix adenocarcinoma 30.8 KRT20 CEACAM5
23 rectum adenocarcinoma 30.8 TP53 PIK3CA MSH6 KRT20 CTNNB1 CEACAM5
24 rectum cancer 30.8 TYMS MSH6 KRT20 CEACAM5 APC
25 mismatch repair cancer syndrome 1 30.7 MSH6 CTNNB1 APC
26 li-fraumeni syndrome 30.7 TP53 PIK3CA MSH6 CTNNB1 CDH1 BAX
27 in situ carcinoma 30.7 TP53 PIK3CA CTNNB1 CDH1
28 bladder urothelial carcinoma 30.7 TP53 PIK3CA KRT20 CTNNB1 CDH1 CASP3
29 cystitis 30.7 TP53 PTGS2 KRT20 CDH1
30 pseudomyxoma peritonei 30.7 TP53 KRT20 CTNNB1 CEACAM5 CDH1
31 renal cell carcinoma, nonpapillary 30.7 TP53 PIK3CA KRT20 CDH1 BRAF ABCB1
32 large intestine adenocarcinoma 30.7 TP53 PIK3CA CTNNB1
33 leukemia, acute lymphoblastic 30.7 TYMS TP53 CASP3 APC ABCB1
34 lung squamous cell carcinoma 30.6 TP53 PIK3CA CTNNB1 CDH1 BRAF
35 urinary tract obstruction 30.6 PTGS2 PIK3CA CDH1
36 ductal carcinoma in situ 30.6 TP53 PTGS2 PIK3CA CDH1
37 colorectal adenoma 30.6 TP53 PTGS2 ODC1 CTNNB1 CDH1 APC
38 skin melanoma 30.6 TP53 PTGS2 PIK3CA CTNNB1 CDH1 CASP3
39 peutz-jeghers syndrome 30.6 TP53 ODC1 CTNNB1 APC
40 malignant astrocytoma 30.6 TP53 CTNNB1 CASP3 BRAF ABCB1
41 adrenal cortical carcinoma 30.6 TP53 PIK3CA CTNNB1 BRAF
42 lymphoma, non-hodgkin, familial 30.6 TP53 RAD54L PIK3CA CASP3 BRAF BAX
43 renal cell carcinoma, papillary, 1 30.6 TP53 PIK3CA CTNNB1 BRAF
44 myeloma, multiple 30.6 TP53 PIK3CA CTNNB1 CASP3 BRAF ABCB1
45 pancreatic adenocarcinoma 30.6 TP53 PTGS2 PIK3CA CTNNB1 BRAF
46 liposarcoma 30.6 TP53 PIK3CA CTNNB1 CASP3
47 neuroblastoma 30.6 TP53 PTGS2 PIK3CA ODC1 CTNNB1 CASP3
48 leukemia, acute myeloid 30.6 TP53 PIK3CA CTNNB1 CDH1 CASP3 ABCB1
49 mantle cell lymphoma 30.6 TP53 PIK3CA CTNNB1 CASP3
50 mature teratoma 30.6 TP53 CEACAM5 BRAF

Graphical network of the top 20 diseases related to Colon Adenocarcinoma:



Diseases related to Colon Adenocarcinoma

Symptoms & Phenotypes for Colon Adenocarcinoma

GenomeRNAi Phenotypes related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.4 APC
2 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.4 MTHFD1L
3 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.4 BRAF
4 Increased shRNA abundance (Z-score > 2) GR00366-A-150 9.4 MTHFD1L
5 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.4 MTHFD1L
6 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.4 MTHFD1L
7 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.4 APC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.4 APC
9 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.4 BRAF CTNNB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-53 9.4 MTHFD1L
11 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.4 PIK3CA

MGI Mouse Phenotypes related to Colon Adenocarcinoma:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 APC BAX BRAF CASP3 CDH1 CTNNB1
2 growth/size/body region MP:0005378 10.29 ABCB1 ACSL4 APC BAX BRAF CASP3
3 endocrine/exocrine gland MP:0005379 10.24 ABCB1 ACSL4 APC BAX BRAF CASP3
4 mortality/aging MP:0010768 10.24 ABCB1 ACSL4 APC BAX BRAF CASP3
5 immune system MP:0005387 10.21 ABCB1 APC BAX BRAF CASP3 CDH1
6 embryo MP:0005380 10.16 APC BRAF CDH1 CTNNB1 MTHFD1L ODC1
7 digestive/alimentary MP:0005381 10.13 ABCB1 APC BRAF CASP3 CDH1 CTNNB1
8 integument MP:0010771 10.06 APC BRAF CASP3 CDH1 CTNNB1 MSH6
9 hearing/vestibular/ear MP:0005377 10 ABCB1 APC BAX BRAF CASP3 CTNNB1
10 muscle MP:0005369 9.92 APC BAX BRAF CASP3 CTNNB1 PIK3CA
11 neoplasm MP:0002006 9.91 APC BAX BRAF CDH1 CTNNB1 MSH6
12 no phenotypic analysis MP:0003012 9.7 ABCB1 CASP3 CDH1 CTNNB1 PIK3CA PTGS2
13 reproductive system MP:0005389 9.7 ABCB1 ACSL4 APC BAX BRAF CASP3
14 vision/eye MP:0005391 9.28 APC BAX BRAF CASP3 CTNNB1 PIK3CA

Drugs & Therapeutics for Colon Adenocarcinoma

Drugs for Colon Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
2
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
3
Bevacizumab Approved, Investigational Phase 3 216974-75-3
4
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
5
Fluorouracil Approved Phase 3 51-21-8 3385
6
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
7
leucovorin Approved Phase 3 58-05-9 6006
8
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
9
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
10
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
11
Dalteparin Approved Phase 3 9005-49-6
12
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
13
Panitumumab Approved, Investigational Phase 2, Phase 3 339177-26-3 50070211
14
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
15
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
16
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
17
Floxuridine Approved Phase 3 50-91-9 5790
18
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
19
Promethazine Approved, Investigational Phase 3 60-87-7 4927
20
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
21
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
22
Eniluracil Investigational Phase 3 59989-18-3
23 Edrecolomab Experimental, Investigational Phase 3 156586-89-9
24
Vatalanib Investigational Phase 3 212141-54-3 151194
25 Antineoplastic Agents, Immunological Phase 3
26 Angiogenesis Inhibitors Phase 3
27 Anti-Arrhythmia Agents Phase 3
28 Anesthetics Phase 3
29 Anticonvulsants Phase 3
30 calcium channel blockers Phase 3
31
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
32 Protein Kinase Inhibitors Phase 3
33 Adjuvants, Immunologic Phase 3
34 Semaxinib Phase 3
35 Immunoglobulin G Phase 3
36 Hematinics Phase 3
37 Fibrinolytic Agents Phase 3
38 Anticoagulants Phase 3
39 calcium heparin Phase 3
40 Platelet Aggregation Inhibitors Phase 3
41 Antipyretics Phase 3
42 Heparin, Low-Molecular-Weight Phase 3
43 Antirheumatic Agents Phase 3
44 Analgesics Phase 3
45 Anti-Inflammatory Agents Phase 3
46 Cyclooxygenase 2 Inhibitors Phase 3
47 Cyclooxygenase Inhibitors Phase 3
48 Analgesics, Non-Narcotic Phase 3
49 Anti-Inflammatory Agents, Non-Steroidal Phase 3
50 Immunoglobulins Phase 3

Interventional clinical trials:

(show top 50) (show all 237)
# Name Status NCT ID Phase Drugs
1 A Randomised Clinical Trial of Treatment for Fluorouracil-Resistant Advanced Colorectal Cancer Comparing Standard Single-Agent Irinotecan Versus Irinotecan Plus Panitumumab and Versus Irinotecan Plus Ciclosporin [Panitumumab, Irinotecan & Ciclosporin in COLOrectal Cancer Therapy (PICCOLO)] Unknown status NCT00389870 Phase 3 cyclosporine;irinotecan hydrochloride
2 A Three-Arm Randomised Controlled Trial Comparing Either Continuous Chemotherapy Plus Cetuximab or Intermittent Chemotherapy With Standard Continuous Palliative Combination Chemotherapy With Oxaliplatin and a Fluoropyrimidine in First Line Treatment of Metastatic Colorectal Cancer (COIN) Unknown status NCT00182715 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
3 Drug Treatment for Bowel Cancer: Making the Best Choices When a Milder Treatment is Needed Unknown status NCT00070213 Phase 3 FOLFOX regimen;capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
4 CHEMOTHERAPY CHOICES IN ADVANCED COLORECTAL CANCER: A RANDOMISED TRIAL COMPARING 2 DURATIONS AND 3 SYSTEMIC CHEMOTHERAPY REGIMENS IN THE PALLIATIVE TREATMENT OF ADVANCED COLORECTAL CANCER Unknown status NCT00002893 Phase 3 fluorouracil;leucovorin calcium;raltitrexed
5 A RANDOMISED TRIAL OF INTRAVENOUS VERSUS INTRAHEPATIC ARTERIAL 5-FU AND LEUCOVORIN FOR COLORECTAL LIVER METASTASES Unknown status NCT00002692 Phase 3 fluorouracil;isolated perfusion;leucovorin calcium
6 Randomized Phase III Intergroup Trial in Resected Stage 2 (Dukes B) Colon Cancer: 6-Month Infusional 5FU-CPT11 (+/- Folinic Acid) Versus Observation - Determination of Biologic Predictive and Response Factors Unknown status NCT00091312 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
7 Multicentre Phase III Comparing To Therapeutic Sequence: Folfiri Following of Folfox6 (Group A) and Folfox6 Following Of (Group B) For Metastatic Colorectal Cancer Unknown status NCT00003260 Phase 3 FOLFIRI regimen;FOLFOX regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
8 Phase II-III Study of an Optimized LV-5FU-Oxaliplatin Strategy in Metastatic Colorectal Cancer. Optimox2 Study. C02-2 Unknown status NCT00274872 Phase 2, Phase 3 fluorouracil;leucovorin calcium;oxaliplatin
9 5-Fluorouracil-Leucovorin With or Without Carboplatin as Adjuvant Treatment for Primary Dukes B2-C Colon Cancer; Chronomodulated Versus Standard Administration. A Multicenter Randomized Phase III Trial of the GRECCR-Belgium (Study 03). Unknown status NCT00046995 Phase 3 carboplatin;fluorouracil;leucovorin calcium
10 A Phase III, Randomized, Open-Label Multicenter, International Study Comparing The Combination Of SU5416/Irinotecan/5-Fluorouracil/Leucovorin Versus Irinotecan/Fluorouracil/Leucovorin Alone As First-Line Therapy Of Patient With Previously Untreated Metastatic Colorectal Cancer Unknown status NCT00021281 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;semaxanib
11 A Multicenter, Open-Label, Randomized, Three-Arm Study Of 5-Fluorouracil (5-FU) Plus Leucovorin (LV) Or Oxaliplatin Or A Combination Of (5-Fu) LV + Oxaliplatin As Second-Line Treatment Of Metastatic Colorectal Carcinoma Unknown status NCT00008281 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
12 Phase III Study of An Optimized LV-5FU-Oxaliplatin Regimen in Metastatic Colorectal Cancer. C99-1. Unknown status NCT00006468 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
13 Phase III Randomized Study of Intensive Adjuvant Chemotherapy for Resected Colon Cancer at High Risk of Recurrence Unknown status NCT00005979 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
14 A Prospective Randomised Open Label Trial of Oxaliplatin/Fluoropyrimidine Versus Oxaliplatin/Fluoropyrimidine Plus Cetuximab Pre and Post Operatively in Patients With Resectable Colorectal Liver Metastasis Requiring Chemotherapy Unknown status NCT00482222 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
15 A Phase III Randomized Trial Investigating the Duration of Adjuvant Therapy(3 Versus 6 Months) With the Modified FOLFOX 6 or XELOX Regimens for Patients With Stage III Colon Cancer Unknown status NCT00958737 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin;XELOX regimen;Capecitabine
16 Pilot / Phase III Randomized Trial Comparing Standard Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin C + Standard Systemic Therapy in Patients With Limited Peritoneal Dissemination of Colon Adenocarcinoma Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
17 Randomized Phase III Trial of Adjuvant Chemotherapy With UFT vs. Observation in Curatively Resected Stage II Colon Cancer Completed NCT00392899 Phase 3 UFT adjuvant chemotherapy
18 A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity Completed NCT00316914 Phase 3 calcium gluconate;magnesium sulfate
19 Randomized Study of Classic vs Simplified Leucovorin Calcium and Fluorouracil With or Without Irinotecan in Patients Aged At Least 75 Years With Advanced Colorectal Cancer Completed NCT00303771 Phase 3 fluorouracil;irinotecan hydrochloride;leucovorin calcium
20 Phase III Study of an Optimized Chemotherapy Followed by Maintenance With Bevacizumab Strategy With or Without Erlotinib in Unresectable Metastatic Colorectal Cancer. DREAM OPTIMOX 3. C04-2 Completed NCT00265824 Phase 3 bevacizumab;bevacizumab, erlotinib
21 Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab Completed NCT00265811 Phase 3 Folfox;Cetuximab
22 A Randomized, Prospective Study Comparing Three Regimens Of Eloxatin ™ Plus Fluoropyrimidine For Evaluation Of Safety And Tolerability In First Line Treatment Of Patients With Advanced Colorectal Cancer (Tree Study) Completed NCT00062426 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
23 Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer Completed NCT00064181 Phase 3 FOLFIRI regimen;capecitabine;celecoxib;fluorouracil;irinotecan hydrochloride;leucovorin calcium
24 Interracial Study of CPT-11 (Irinotecan) Pharmacokinetics in 5-Fluorouracil Refractory Colorectal Cancer: A Population Pharmacokinetic/Pharmacodynamic Study of CPT-11 Completed NCT00006103 Phase 3 fluorouracil;irinotecan hydrochloride;leucovorin calcium
25 A Randomized, Open-Label, Multicenter Phase III Study of 5-FU/Leucovorin With or Without Concomitant SU5416 in Patients With Metastatic Colorectal Cancer Completed NCT00004252 Phase 3 fluorouracil;leucovorin calcium;semaxanib
26 Pan-European Trials in Adjuvant Colon Cancer (PETACC-2): Randomized Phase III Intergroup Trial of High-Dose Infusional 5-FU (+ or - Folinic Acid) Versus Standard Bolus 5-FU/Folinic Acid Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
27 First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial Completed NCT00003287 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
28 A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity Completed NCT01099449 Phase 3 calcium gluconate;magnesium sulfate;oxaliplatin
29 Essai De Phase III De Chimiotherapie Par FOLFOX 4 Ou Par Une Succession FOLFOX 7 - FOLFIRI Chez Des Patients Ayant Des Metastases Resecables D'Origine Colorectale - MIROX Completed NCT00268398 Phase 3 oxaliplatin, folinic acid, fluorouracil;oxaliplatin, irinotecan, folinic acid, fluorouracil
30 A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU/ Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum Completed NCT00265850 Phase 3 FOLFOX or;FOLFIRI
31 CPT-11 in Combination With Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Relative to Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Alone in Patients With Advanced Colorectal Cancer Completed NCT00004885 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
32 A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum Completed NCT00003594 Phase 3 irinotecan;fluorouracil;leucovorin calcium;oxaliplatin
33 PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER Completed NCT00002716 Phase 3 dexamethasone;floxuridine;fluorouracil;leucovorin calcium
34 A Clinical Trial to Evaluate the Postoperative Portal Vein Infusion of 5-Fluorouracil and Heparin in Patients With Resectable Adenocarcinoma of the Colon Completed NCT00427310 Phase 3 fluorouracil;sodium heparin
35 A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus Leucovorin (LV) With 5-Fluorouracil (5-FU) Plus LV in the Treatment of Patients With Stages II And III Carcinoma of the Colon Completed NCT00378716 Phase 3 5-fluorouracil;leucovorin calcium;tegafur;uracil
36 Multicenter, Double-Blind, Placebo-Controlled Randomized Phase III Study of Adjuvant Therapy With Celecoxib in Combination With Chemotherapy in Patients With Curatively Resected Stage III Colon Cancer Completed NCT00085163 Phase 3 celecoxib;fluorouracil;leucovorin calcium
37 Multicenter Phase III Open Label Randomized Trial Comparing CPT-11 In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone As Adjuvant Treatment Of Stage III Colon Cancer Completed NCT00026273 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
38 Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing: A Randomized Trial to Assess the Role of Irinotecan and Oxaliplatin in Advanced Colorectal Cancer Completed NCT00008060 Phase 3 FOLFIRI regimen;FOLFOX regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
39 A PHASE III PROSPECTIVE RANDOMIZED TRIAL COMPARING LAPAROSCOPIC-ASSISTED COLECTOMY VERSUS OPEN COLECTOMY FOR COLON CANCER Completed NCT00002575 Phase 3
40 Randomized Phase III Study of UFT+Leucovorin vs. TS-1 as Adjuvant Treatment for Stage III Colon Cancer , and Investigate Predictive Factors Based on Gene Expression Completed NCT00660894 Phase 3 folinate calcium;tegafur-uracil;tegafur-gimeracil-oteracil potassium
41 FOCUS 3 - A Study to Determine the Feasibility of Molecular Selection of Therapy Using KRAS, BRAF and Topo-1 in Patients With Metastatic or Locally Advanced Colorectal Cancer Completed NCT00975897 Phase 2, Phase 3 fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
42 A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma of the Colon Completed NCT00096278 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
43 A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer Completed NCT00079274 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil;Locally Directed Therapy
44 A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
45 Phase III Trial Comparing a 28 Day Schedule of Daily Oral 5-FU Plus Eniluracil to Protracted Intravenous Infusion in Previously Untreated Patients With Advanced Colorectal Cancer Completed NCT00003873 Phase 3 fluorouracil;eniluracil
46 Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for Patients With Stage III Colon Cancer Completed NCT00003835 Phase 3 leucovorin calcium;fluorouracil;irinotecan hydrochloride
47 Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon Completed NCT00002968 Phase 3
48 Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer Completed NCT00025337 Phase 3 oxaliplatin;leucovorin calcium;fluorouracil
49 A Randomized, Double-blind, Placebo-controlled, Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo Completed NCT00056459 Phase 3 Vatalanib
50 A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum Completed NCT00056446 Phase 3 Vatalanib

Search NIH Clinical Center for Colon Adenocarcinoma

Genetic Tests for Colon Adenocarcinoma

Anatomical Context for Colon Adenocarcinoma

MalaCards organs/tissues related to Colon Adenocarcinoma:

40
Colon, Liver, Lymph Node, Endothelial, T Cells, Breast, Prostate

Publications for Colon Adenocarcinoma

Articles related to Colon Adenocarcinoma:

(show top 50) (show all 4699)
# Title Authors PMID Year
1
Mutations in the RAD54 recombination gene in primary cancers. 6
10362365 1999
2
Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo. 54 61
20107900 2010
3
TAF4b and Jun/activating protein-1 collaborate to regulate the expression of integrin alpha6 and cancer cell migration properties. 61 54
20353996 2010
4
Selective suicide gene therapy of colon cancer exploiting the urokinase plasminogen activator receptor promoter. 61 54
20199127 2010
5
Extracellular ATP activates MAP kinase cascades through a P2Y purinergic receptor in the human intestinal Caco-2 cell line. 61 54
19836435 2009
6
Differences in TRAIL-induced changes of Mcl-1 expression among distinct human colon epithelial cell lines. 54 61
19782681 2009
7
BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. 61 54
19881948 2009
8
Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells. 54 61
19794924 2009
9
No functional and transductional significance of specific neuropilin 1 siRNA inhibition in colon carcinoma cell lines lacking VEGF receptor 2. 61 54
19360289 2009
10
Chemopreventive effects of polysaccharides extract from Asterina pectinifera on HT-29 human colon adenocarcinoma cells. 61 54
19470241 2009
11
Soy isoflavones modulate azoxymethane-induced rat colon carcinogenesis exposed pre- and postnatally and inhibit growth of DLD-1 human colon adenocarcinoma cells by increasing the expression of estrogen receptor-beta. 61 54
19141699 2009
12
Sodium butyrate sensitizes human colon adenocarcinoma COLO 205 cells to both intrinsic and TNF-alpha-dependent extrinsic apoptosis. 61 54
19130237 2009
13
Human caspase-3 inhibition by Z-tLeu-Asp-H: tLeu(P2) counterbalances Asp(P4) and Glu(P3) specific inhibitor truncation. 61 54
18854175 2008
14
Wild-type APC regulates caveolin-1 expression in human colon adenocarcinoma cell lines via FOXO1a and C-myc. 54 61
18444242 2008
15
Resveratrol directly targets COX-2 to inhibit carcinogenesis. 61 54
18381589 2008
16
ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. 54 61
19014651 2008
17
Smad7 induces hepatic metastasis in colorectal cancer. 61 54
18781153 2008
18
Upregulation of annexin A1 expression by butyrate in human colon adenocarcinoma cells: role of p53, NF-Y, and p38 mitogen-activated protein kinase. 61 54
18541673 2008
19
Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies. 61 54
18457384 2008
20
Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. 54 61
18332086 2008
21
Cysteine 62 of Bax is critical for its conformational activation and its proapoptotic activity in response to H2O2-induced apoptosis. 61 54
18344566 2008
22
The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. 61 54
18855679 2008
23
Bap29varP, a variant of Bap29, influences the cell surface expression of the human P-glycoprotein. 54 61
18097552 2008
24
Cyclin-dependent kinase 2/cyclin E complex is involved in p120 catenin (p120ctn)-dependent cell growth control: a new role for p120ctn in cancer. 61 54
17942908 2007
25
Necrosis predominates in the cell death of human colon adenocarcinoma HT-29 cells treated under variable conditions of photodynamic therapy with hypericin. 54 61
17609769 2007
26
Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor. 54 61
17541169 2007
27
Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored beta-glucuronidase. 61 54
17235292 2007
28
Site-specific bidirectional efflux of 2,4-dinitrophenyl-S-glutathione, a substrate of multidrug resistance-associated proteins, in rat intestine and Caco-2 cells. 54 61
17430634 2007
29
Effects of the flavonoid biochanin A on gene expression in primary human hepatocytes and human intestinal cells. 61 54
17340576 2007
30
Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells. 61 54
16909108 2007
31
NF-kappaB/PPAR gamma and/or AP-1/PPAR gamma 'on/off' switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression. 54 61
16506021 2007
32
Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. 61 54
17727795 2007
33
Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. 61 54
17311703 2007
34
Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes. 61 54
17106246 2006
35
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production. 61 54
16458424 2006
36
Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. 54 61
17085643 2006
37
[Inhibition of cell proliferation and C-myc cancer protein expression in human colon adenocarcinoma cell line HT29 with VIP-131I-ASON]. 61 54
17121362 2006
38
Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors. 61 54
16568206 2006
39
Neurotensin receptors in adeno- and squamous cell carcinoma. 61 54
17094477 2006
40
Pre-treatment of HT-29 cells with 5-LOX inhibitor (MK-886) induces changes in cell cycle and increases apoptosis after photodynamic therapy with hypericin. 54 61
16545574 2006
41
Concomitant cell growth and differentiation are dependent on erbB1 and integrin activation in an autonomously surviving colon adenocarcinoma: involvement of autocrine amphiregulin secretion. 54 61
16886596 2006
42
Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc. 61 54
16854083 2006
43
Role of Smad proteins in the regulation of NF-kappaB by TGF-beta in colon cancer cells. 61 54
16288847 2006
44
In-vivo imaging of tumor associated urokinase-type plasminogen activator activity. 61 54
16822063 2006
45
9-Hydroxystearic acid interferes with EGF signalling in a human colon adenocarcinoma. 54 61
16487928 2006
46
An increase in the number of adhesion proteins with altered expression is associated with an increased risk of cancer death for colon carcinoma patients. 54 61
15937692 2006
47
Sphingosine kinase 1 is up-regulated in colon carcinogenesis. 54 61
16319132 2006
48
Molokhia (Corchorus olitorius L.) extract suppresses transformation of the aryl hydrocarbon receptor induced by dioxins. 61 54
16115717 2006
49
Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. 54 61
15922743 2005
50
Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. 61 54
15930282 2005

Variations for Colon Adenocarcinoma

ClinVar genetic disease variations for Colon Adenocarcinoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RAD54L NM_003579.4(RAD54L):c.188C>A (p.Pro63His) SNV Pathogenic 6191 rs121908688 1:46715769-46715769 1:46250097-46250097
2 MSH6 NM_000179.2(MSH6):c.1808dup (p.Glu604fs) Duplication Pathogenic 560013 rs1553413200 2:48026927-48026928 2:47799788-47799789
3 APC NM_000038.6(APC):c.3922_3926AAAGA[1] (p.Glu1309fs) Microsatellite Pathogenic 816 rs121913224 5:112175212-112175216 5:112839515-112839519
4 APC NM_000038.6(APC):c.7832C>T (p.Thr2611Ile) SNV Uncertain significance 133523 rs587778037 5:112179123-112179123 5:112843426-112843426
5 APC NM_000038.6(APC):c.1463T>C (p.Leu488Pro) SNV Uncertain significance 559962 rs368434773 5:112162859-112162859 5:112827162-112827162

Cosmic variations for Colon Adenocarcinoma:

9 (show top 50) (show all 33543)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263736 ZRSR2 large intestine,colon,carcinoma,NS c.553G>T p.D185Y 23:15809314-15809314 3
2 COSM88261539 ZRSR2 large intestine,colon,carcinoma,NS c.917G>A p.R306Q 23:15820296-15820296 3
3 COSM95950816 ZNHIT6 large intestine,colon,carcinoma,NS c.1364T>A p.L455H 1:85657855-85657855 3
4 COSM110240486 ZNHIT6 large intestine,colon,carcinoma,NS c.1247T>A p.L416H 1:85657855-85657855 3
5 COSM86861594 ZNHIT1 large intestine,colon,carcinoma,NS c.400C>T p.R134W 7:101223799-101223799 3
6 COSM98771566 ZNF813 large intestine,colon,carcinoma,NS c.1639G>A p.G547R 19:53491871-53491871 3
7 COSM91871130 ZNF536 large intestine,colon,carcinoma,NS c.1158G>T p.W386C 19:30444720-30444720 3
8 COSM91870713 ZNF536 large intestine,colon,carcinoma,NS c.2533C>G p.L845V 19:30548152-30548152 3
9 COSM94777824 ZNF521 large intestine,colon,carcinoma,NS c.3524C>T p.T1175M 18:25224394-25224394 3
10 COSM131481019 ZNF521 large intestine,rectum,carcinoma,NS c.799G>C p.E267Q 18:25227119-25227119 3
11 COSM94774956 ZNF521 large intestine,rectum,carcinoma,NS c.799G>C p.E267Q 18:25227119-25227119 3
12 COSM140705261 ZNF521 large intestine,colon,carcinoma,NS c.2864C>T p.T955M 18:25224394-25224394 3
13 COSM140703236 ZNF521 large intestine,rectum,carcinoma,NS c.139G>C p.E47Q 18:25227119-25227119 3
14 COSM131484378 ZNF521 large intestine,colon,carcinoma,NS c.3524C>T p.T1175M 18:25224394-25224394 3
15 COSM86916483 ZNF280D large intestine,colon,carcinoma,NS c.2020A>C p.R674= 15:56658461-56658461 3
16 COSM136198199 ZNF280D large intestine,colon,carcinoma,NS c.1981A>C p.R661= 15:56658461-56658461 3
17 COSM84512904 ZNF276 large intestine,colon,carcinoma,NS c.*438C>T p.? 16:89738684-89738684 3
18 COSM84507966 ZNF276 large intestine,colon,carcinoma,NS c.*664G>A p.? 16:89738910-89738910 3
19 COSM95251466 ZNF217 large intestine,colon,carcinoma,NS c.967G>A p.D323N 20:53581860-53581860 3
20 COSM88695903 ZNF217 large intestine,colon,carcinoma,NS c.967G>A p.D323N 20:53581860-53581860 3
21 COSM88697637 ZNF155 large intestine,colon,carcinoma,NS c.1421A>G p.H474R 19:43997278-43997278 3
22 COSM141944208 ZNF155 large intestine,colon,carcinoma,NS c.1421A>G p.H474R 19:43997278-43997278 3
23 COSM105811781 ZNF155 large intestine,colon,carcinoma,NS c.1454A>G p.H485R 19:43997278-43997278 3
24 COSM140959108 ZNF155 large intestine,colon,carcinoma,NS c.1421A>G p.H474R 19:43997278-43997278 3
25 COSM110017805 ZMIZ2 large intestine,colon,carcinoma,NS c.1850G>A p.R617H 7:44763403-44763403 3
26 COSM110177741 ZMIZ2 large intestine,colon,carcinoma,NS c.1754G>A p.R585H 7:44763403-44763403 3
27 COSM142570150 ZMIZ2 large intestine,colon,carcinoma,NS c.1859G>A p.R620H 7:44763403-44763403 3
28 COSM102902058 ZMIZ2 large intestine,colon,carcinoma,NS c.1676G>A p.R559H 7:44763403-44763403 3
29 COSM89535029 ZMIZ2 large intestine,colon,carcinoma,NS c.1850G>A p.R617H 7:44763403-44763403 3
30 COSM84914866 ZMIZ2 large intestine,colon,carcinoma,NS c.1772G>A p.R591H 7:44763403-44763403 3
31 COSM127394330 ZFHX4 large intestine,rectum,carcinoma,NS c.8291C>T p.P2764L 8:76855212-76855212 3
32 COSM127388315 ZFHX4 large intestine,colon,carcinoma,NS c.681C>A p.F227L 8:76704769-76704769 3
33 COSM125167414 ZFHX4 large intestine,rectum,carcinoma,NS c.8213C>T p.P2738L 8:76855212-76855212 3
34 COSM125161701 ZFHX4 large intestine,colon,carcinoma,NS c.681C>A p.F227L 8:76704769-76704769 3
35 COSM102026679 ZFHX3 large intestine,colon,carcinoma,NS c.4748C>T p.S1583L 16:72795192-72795192 3
36 COSM149275347 ZFHX3 large intestine,colon,carcinoma,NS c.7928G>A p.R2643H 16:72794754-72794754 3
37 COSM87283250 ZFHX3 large intestine,rectum,carcinoma,NS c.7279G>A p.D2427N 16:72795403-72795403 3
38 COSM87290885 ZFHX3 large intestine,rectum,carcinoma,NS c.8875A>G p.K2959E 16:72793807-72793807 3
39 COSM102030577 ZFHX3 large intestine,colon,carcinoma,NS c.2813A>C p.Q938P 16:72797127-72797127 3
40 COSM102039141 ZFHX3 large intestine,colon,carcinoma,NS c.6725G>A p.S2242N 16:72788809-72788809 3
41 COSM102047808 ZFHX3 large intestine,colon,carcinoma,NS c.7255C>A p.Q2419K 16:72788279-72788279 3
42 COSM87287972 ZFHX3 large intestine,colon,carcinoma,NS c.7381G>A p.E2461K 16:72795301-72795301 3
43 COSM149294291 ZFHX3 large intestine,colon,carcinoma,NS c.392G>T p.G131V 16:72959754-72959754 3
44 COSM102035995 ZFHX3 large intestine,colon,carcinoma,NS c.-23-7558G>C p.? 16:72958523-72958523 3
45 COSM102038517 ZFHX3 large intestine,colon,carcinoma,NS c.4639G>A p.E1547K 16:72795301-72795301 3
46 COSM149316595 ZFHX3 large intestine,rectum,carcinoma,NS c.4628G>A p.R1543H 16:72798054-72798054 3
47 COSM149297634 ZFHX3 large intestine,colon,carcinoma,NS c.9227T>G p.M3076R 16:72793455-72793455 3
48 COSM87287954 ZFHX3 large intestine,colon,carcinoma,NS c.7804A>G p.T2602A 16:72794878-72794878 3
49 COSM149331878 ZFHX3 large intestine,colon,carcinoma,NS c.2548C>A p.L850I 16:72957598-72957598 3
50 COSM87296576 ZFHX3 large intestine,colon,carcinoma,NS c.9997C>A p.Q3333K 16:72788279-72788279 3

Expression for Colon Adenocarcinoma

Search GEO for disease gene expression data for Colon Adenocarcinoma.

Pathways for Colon Adenocarcinoma

Pathways related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 TP53 PTGS2 PIK3CA CTNNB1 CASP3 BRAF
2
Show member pathways
13.04 TP53 PIK3CA CTNNB1 CASP3 BRAF BAX
3
Show member pathways
12.94 TP53 PTGS2 PIK3CA CTNNB1 CASP3 BAX
4
Show member pathways
12.93 TP53 PTGS2 PIK3CA CTNNB1 CASP3 BAX
5
Show member pathways
12.72 TP53 PIK3CA MSH6 CTNNB1 CDH1 CASP3
6
Show member pathways
12.64 TP53 PIK3CA CTNNB1 CDH1 BRAF BAX
7
Show member pathways
12.6 TP53 PIK3CA MSH6 CDH1 BRAF BAX
8 12.58 TP53 PTGS2 PIK3CA MSH6 CTNNB1 CDH1
9
Show member pathways
12.54 TP53 PTGS2 PIK3CA CTNNB1 CDH1 CASP3
10
Show member pathways
12.49 TP53 PIK3CA CTNNB1 CDH1 CASP3
11 12.48 TP53 PTGS2 PIK3CA CASP3 APC ABCB1
12
Show member pathways
12.42 TP53 PIK3CA CTNNB1 CASP3 BAX
13 12.41 TP53 PTGS2 CTNNB1 CDH1 APC
14
Show member pathways
12.39 PTGS2 PIK3CA CTNNB1 BRAF
15
Show member pathways
12.38 PIK3CA CTNNB1 CDH1 BRAF APC
16
Show member pathways
12.33 PIK3CA CTNNB1 CDH1 BRAF
17 12.28 TP53 PIK3CA CASP3 BAX
18
Show member pathways
12.27 TP53 PIK3CA CTNNB1 BAX APC
19 12.25 TP53 PIK3CA CTNNB1 CASP3 BRAF
20
Show member pathways
12.23 TP53 PIK3CA CASP3 BRAF BAX
21
Show member pathways
12.13 TP53 CASP3 BRAF BAX
22 12.1 CTNNB1 CDH1 CASP3 APC
23
Show member pathways
11.98 CTNNB1 CDH1 CASP3 APC
24 11.95 TP53 CTNNB1 BRAF APC
25 11.92 TP53 PIK3CA CTNNB1 BAX APC
26 11.85 CTNNB1 CASP3 BRAF
27 11.83 TYMS TP53 MSH6
28 11.83 TP53 PTGS2 MSH6 CTNNB1 CDH1 CASP3
29
Show member pathways
11.79 PIK3CA CASP3 BRAF BAX
30 11.79 TP53 PTGS2 PIK3CA CASP3 BAX
31 11.78 TP53 ODC1 BAX
32 11.77 CTNNB1 CDH1 APC
33 11.77 TP53 BRAF BAX
34 11.75 PIK3CA CTNNB1 CDH1
35 11.72 TP53 CDH1 BRAF
36
Show member pathways
11.67 TP53 PIK3CA CASP3
37 11.67 TP53 PIK3CA MSH6 CASP3 BAX
38 11.61 PTGS2 CTNNB1 CASP3
39 11.55 TP53 PTGS2 CASP3
40 11.53 TP53 PIK3CA CASP3 APC
41 11.46 TP53 RAD54L ODC1 MSH6 CTNNB1 CDH1
42 11.44 TP53 MSH6 CASP3 BAX
43 11.39 TP53 CASP3 BAX
44 11.38 TP53 PTGS2 BAX
45 11.32 PIK3CA CTNNB1 CDH1
46 11.17 TP53 CASP3 BAX
47 11.16 PIK3CA CTNNB1 CDH1
48 11.11 CASP3 BAX ABCB1
49 10.82 CTNNB1 CDH1
50 10.78 TP53 ABCB1

GO Terms for Colon Adenocarcinoma

Cellular components related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral plasma membrane GO:0016328 9.43 CTNNB1 CDH1 APC
2 beta-catenin destruction complex GO:0030877 9.37 CTNNB1 APC
3 Wnt signalosome GO:1990909 9.32 CTNNB1 APC
4 lamellipodium GO:0030027 9.26 PIK3CA CTNNB1 CDH1 APC
5 flotillin complex GO:0016600 9.16 CTNNB1 CDH1
6 catenin complex GO:0016342 8.8 CTNNB1 CDH1 APC

Biological processes related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.97 TP53 PTGS2 CTNNB1 BAX APC
2 negative regulation of apoptotic process GO:0043066 9.88 TP53 PTGS2 CTNNB1 CEACAM5 CASP3 BRAF
3 regulation of cell proliferation GO:0042127 9.86 TP53 PTGS2 CTNNB1 BRAF
4 cellular response to DNA damage stimulus GO:0006974 9.8 TP53 RAD54L MSH6 CASP3 BAX APC
5 response to toxic substance GO:0009636 9.78 TYMS CDH1 BAX
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.77 PTGS2 PIK3CA BRAF
7 response to organic substance GO:0010033 9.77 PTGS2 CDH1 CASP3
8 response to glucocorticoid GO:0051384 9.72 TYMS PTGS2 CASP3
9 cellular response to UV GO:0034644 9.69 TP53 PTGS2 BAX
10 response to UV GO:0009411 9.65 TP53 MSH6 CASP3
11 positive regulation of apoptotic process GO:0043065 9.63 TP53 PTGS2 CTNNB1 CASP3 BAX APC
12 neuron apoptotic process GO:0051402 9.61 TP53 CASP3 BAX
13 tetrahydrofolate interconversion GO:0035999 9.58 TYMS MTHFD1L
14 response to salt stress GO:0009651 9.58 TP53 BAX
15 entry of bacterium into host cell GO:0035635 9.54 CTNNB1 CDH1
16 intrinsic apoptotic signaling pathway GO:0097193 9.54 TP53 MSH6 BAX
17 DNA strand renaturation GO:0000733 9.52 TP53 RAD54L
18 regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902108 9.49 TP53 BAX
19 cellular response to indole-3-methanol GO:0071681 9.46 CTNNB1 CDH1
20 determination of adult lifespan GO:0008340 9.43 TP53 RAD54L MSH6
21 positive regulation of neuron apoptotic process GO:0043525 9.26 TP53 CTNNB1 CASP3 BAX
22 response to drug GO:0042493 9.23 TYMS TP53 RAD54L PTGS2 CTNNB1 CDH1

Molecular functions related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.56 TP53 RAD54L PIK3CA MTHFD1L MSH6 BRAF
2 beta-catenin binding GO:0008013 9.33 CTNNB1 CDH1 APC
3 gamma-catenin binding GO:0045295 9.26 CDH1 APC
4 protein homodimerization activity GO:0042803 9.17 TYMS PTGS2 ODC1 MTHFD1L MSH6 CEACAM5

Sources for Colon Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....